Study on Iberdomide and Daratumumab as Maintenance Therapy After Stem Cell Transplant for Multiple Myeloma

Sponsor: Barbara Ann Karmanos Cancer Institute

Sponsor score: 40

ClinicalTrials ID:NCT06107738

Provider View

This clinical trial is exploring whether a combination of Iberdomide and Daratumumab can help patients with Multiple Myeloma who still have some cancer cells after a stem cell transplant. The study aims to find out if this treatment is effective and safe for these patients.

Patient Parameters

Program Overview

The purpose of this phase 2 study is to see if Iberdomide and Daratumumab can help patients with Multiple Myeloma who still have minimal residual disease (small amounts of cancer cells) after their initial treatment, including a stem cell transplant. The study will assess if this combination is effective in controlling the disease and if it is safe for patients to use as a maintenance therapy. Participants will undergo various tests and assessments to determine their eligibility and will receive the treatment over a series of cycles, with regular check-ups to monitor their health and the treatment's effects.

Eligibility Criteria

Inclusion Criteria

  • Have Multiple Myeloma and received prior treatment with Daratumumab, showing at least a partial response.
  • Completed a stem cell transplant 90-150 days before joining the study, with no further treatment or disease progression since then.
  • Have minimal residual disease (MRD positive) as confirmed by specific tests after the transplant.
  • Be in good general health with a performance status score of 0 to 2.
  • Have adequate blood cell counts and organ function as determined by specific tests.
  • Women of childbearing potential must have a negative pregnancy test and agree to use effective birth control during the study and for a specified period after.
  • Men must agree to use condoms during sexual contact with women of childbearing potential and not donate sperm during the study and for a specified period after.
  • Be informed about the study and agree to sign a consent form.
  • Be 18 years or older.

Exclusion Criteria

  • Have active HIV or hepatitis C, or a positive test for hepatitis B.
  • Unable to assess MRD status or MRD negative at the required level.
  • Had a heart attack or stroke within 90 days before joining the study.
  • Unable to tolerate required preventive medications for blood clots or infections.
  • Had major surgery within 28 days before joining the study.
  • Have medical conditions that make it unsafe to participate, such as severe heart problems.
  • Had to stop previous Daratumumab treatment due to side effects.
  • Have another type of cancer unless it was treated and resolved at least two years ago.
  • Have lung conditions like severe asthma or COPD that are not well-controlled.
  • Have allergies or intolerances to certain medications used in the study.
  • Be pregnant or breastfeeding, or planning to become pregnant or father a child during the study or shortly after.
  • Have a prolonged QT interval on an ECG test.
  • Use certain medications that affect liver enzymes within 14 days before starting the study treatment.

Locations

FACILITYZIPCITYSTATE
Karmanos Cancer Institute48201DetroitMichigan
KCI at McLaren Greater Lansing48910LansingMichigan

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.